MHE November 2021

November 12, 2021

Site of service has a major effect on the cost. Home infusion and oral formulations are challenging both hospital- and physician-based infusions.

November 11, 2021

Treating high levels of low-density lipoprotein cholesterol in young people may reduce lifetime exposure and lead to fewer cases of coronary heart disease.

November 10, 2021

Diabetes and obesity rates are high among Latinos. To lower them, providers and payers need to understand cultural factors and barriers to healthcare.

November 09, 2021

The Pfizer and Moderna COVID-19 vaccines introduced much of the world to ribonucleic acid (RNA), which has long played second fiddle to DNA. But in addition to the messenger RNA vaccines, treatments targeting and using RNA in a variety of ways are filling the pipeline and exciting researchers and drug developers.

November 08, 2021

The agency has been in the spotlight because of the pandemic, questions about its independence and the approval of Aduhelm. The stakes are high and the politics, fraught.

November 05, 2021

Safety concerns may limit JAK inhibitors as treatment for the common skin condition.

November 04, 2021

Investor funding for digital healthcare ventures during the first three quarters of 2021 has already far outpaced last year’s levels, surpassing $20 billion for the first time

November 03, 2021

Drugs that the FDA has approved on its fast-track accelerated approval basis are making up an increasingly larger share of Medicaid spending on pharmaceuticals.

November 03, 2021

Having CMS negotiate drug prices is a policy favored by President Joe Biden and many Democrats, and it is a prominent feature of H.R. 3, also known as the Elijah Cummings Lower Drug Costs Now Act.